Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 411

1.

Prevalence of cardiac comorbidities, and their underdetection and contribution to exertional symptoms in COPD: results from the COSYCONET cohort.

Alter P, Mayerhofer BA, Kahnert K, Watz H, Waschki B, Andreas S, Biertz F, Bals R, Vogelmeier CF, Jörres RA.

Int J Chron Obstruct Pulmon Dis. 2019 Sep 20;14:2163-2172. doi: 10.2147/COPD.S209343. eCollection 2019.

2.

Low miR-150-5p and miR-320b Expression Predicts Reduced Survival of COPD Patients.

Keller A, Ludwig N, Fehlmann T, Kahraman M, Backes C, Kern F, Vogelmeier CF, Diener C, Fischer U, Biertz F, Herr C, Jörres RA, Lenhof HP, Bals R, Meese E.

Cells. 2019 Sep 27;8(10). pii: E1162. doi: 10.3390/cells8101162.

3.

Comparative effectiveness of triple therapy versus dual bronchodilation in COPD.

Voorham J, Corradi M, Papi A, Vogelmeier CF, Singh D, Fabbri LM, Kerkhof M, Kocks JH, Carter V, Price D.

ERJ Open Res. 2019 Aug 30;5(3). pii: 00106-2019. doi: 10.1183/23120541.00106-2019. eCollection 2019 Jul.

4.

Anti-interleukin-5 therapy (mepolizumab) in life-threatening asthma attack: A case-based discussion.

Tello K, Hoffmann A, Beutel B, Greulich T, Vogelmeier CF, Richter MJ, Kuhnert S, Böselt T, Alter P, Holland A, Idzko M, Buhl R, Koczulla AR.

Respir Med Case Rep. 2019 Aug 22;28:100927. doi: 10.1016/j.rmcr.2019.100927. eCollection 2019.

5.

Efficacy and safety of inhaled alpha-1-antitrypsin in patients with severe alpha-1-antitrypsin deficiency and frequent exacerbations of Chronic Obstructive Pulmonary Disease.

Stolk J, Tov N, Chapman KR, Fernandez P, MacNee W, Hopkinson NS, Piitulainen E, Seersholm N, Vogelmeier CF, Bals R, McElvaney G, Stockley RA.

Eur Respir J. 2019 Aug 29. pii: 1900673. doi: 10.1183/13993003.00673-2019. [Epub ahead of print]

PMID:
31467115
6.

[Screening and check-ups in pneumology].

Kroenig J, Holland A, Vogelmeier CF.

Dtsch Med Wochenschr. 2019 Aug;144(17):1202-1207. doi: 10.1055/a-0818-8200. Epub 2019 Aug 27. German.

PMID:
31454842
7.

Evaluation of exacerbations and blood eosinophils in UK and US COPD populations.

Vogelmeier CF, Kostikas K, Fang J, Tian H, Jones B, Morgan CL, Fogel R, Gutzwiller FS, Cao H.

Respir Res. 2019 Aug 7;20(1):178. doi: 10.1186/s12931-019-1130-y.

8.

Personalized medicine for patients with COPD: where are we?

Franssen FM, Alter P, Bar N, Benedikter BJ, Iurato S, Maier D, Maxheim M, Roessler FK, Spruit MA, Vogelmeier CF, Wouters EF, Schmeck B.

Int J Chron Obstruct Pulmon Dis. 2019 Jul 9;14:1465-1484. doi: 10.2147/COPD.S175706. eCollection 2019.

9.

Determinants of healthcare utilization and costs in COPD patients: first longitudinal results from the German COPD cohort COSYCONET.

Byng D, Lutter JI, Wacker ME, Jörres RA, Liu X, Karrasch S, Schulz H, Vogelmeier C, Holle R.

Int J Chron Obstruct Pulmon Dis. 2019 Jul 5;14:1423-1439. doi: 10.2147/COPD.S201899. eCollection 2019.

10.

Consequences of chronic kidney disease in chronic obstructive pulmonary disease.

Trudzinski FC, Alqudrah M, Omlor A, Zewinger S, Fliser D, Speer T, Seiler F, Biertz F, Koch A, Vogelmeier C, Welte T, Watz H, Waschki B, Fähndrich S, Jörres R, Bals R; German COSYCONET consortium.

Respir Res. 2019 Jul 12;20(1):151. doi: 10.1186/s12931-019-1107-x.

11.

It is time for the world to take COPD seriously: a statement from the GOLD board of directors.

Halpin DMG, Celli BR, Criner GJ, Frith P, López Varela MV, Salvi S, Vogelmeier CF, Chen R, Mortimer K, Montes de Oca M, Aisanov Z, Obaseki D, Decker R, Agusti A.

Eur Respir J. 2019 Jul 4;54(1). pii: 1900914. doi: 10.1183/13993003.00914-2019. Print 2019 Jul. No abstract available.

PMID:
31273036
12.

Combined effects of lung function, blood gases and kidney function on the exacerbation risk in stable COPD: Results from the COSYCONET cohort.

Trudzinski FC, Kahnert K, Vogelmeier CF, Alter P, Seiler F, Fähndrich S, Watz H, Welte T, Speer T, Zewinger S, Biertz F, Kauczor HU, Jörres RA, Bals R; COSYCONET consortium.

Respir Med. 2019 Jul - Aug;154:18-26. doi: 10.1016/j.rmed.2019.06.007. Epub 2019 Jun 11.

PMID:
31203096
13.

Prevalence and Characteristics of Asthma-Chronic Obstructive Pulmonary Disease Overlap in Routine Primary Care Practices.

Krishnan JA, Nibber A, Chisholm A, Price D, Bateman ED, Bjermer L, van Boven JFM, Brusselle G, Costello RW, Dandurand RJ, Diamant Z, Van Ganse E, Gouder C, van Kampen SC, Kaplan A, Kocks J, Miravitlles M, Niimi A, Pizzichini E, Rhee CK, Soriano JB, Vogelmeier C, Román-Rodriguez M, Carter V, D'Urzo AD, Roche N.

Ann Am Thorac Soc. 2019 Sep;16(9):1143-1150. doi: 10.1513/AnnalsATS.201809-607OC.

PMID:
31162945
14.

Inhaled corticosteroid use by exacerbations and eosinophils: a real-world COPD population.

Vestbo J, Vogelmeier CF, Small M, Siddall J, Fogel R, Kostikas K.

Int J Chron Obstruct Pulmon Dis. 2019 Apr 16;14:853-861. doi: 10.2147/COPD.S189585. eCollection 2019.

15.

Benralizumab for the Prevention of COPD Exacerbations.

Criner GJ, Celli BR, Brightling CE, Agusti A, Papi A, Singh D, Sin DD, Vogelmeier CF, Sciurba FC, Bafadhel M, Backer V, Kato M, Ramírez-Venegas A, Wei YF, Bjermer L, Shih VH, Jison M, O'Quinn S, Makulova N, Newbold P, Goldman M, Martin UJ; GALATHEA Study Investigators; TERRANOVA Study Investigators.

N Engl J Med. 2019 Sep 12;381(11):1023-1034. doi: 10.1056/NEJMoa1905248. Epub 2019 May 20.

PMID:
31112385
16.

["Digitalization in Internal Medicine" - not "Digitalization of Internal Medicine" - a Promising Perspective from Non-Digital Natives].

Vogelmeier CF, Köhler F.

Dtsch Med Wochenschr. 2019 Apr;144(7):425. doi: 10.1055/a-0746-5964. Epub 2019 Mar 29. German. No abstract available.

PMID:
30925594
17.

[Digital medicine].

Hasenfuß G, Vogelmeier CF.

Internist (Berl). 2019 Apr;60(4):317-318. doi: 10.1007/s00108-019-0594-7. German. No abstract available.

PMID:
30923862
18.

Effects of airway obstruction and hyperinflation on electrocardiographic axes in COPD.

Alter P, Watz H, Kahnert K, Rabe KF, Biertz F, Fischer R, Jung P, Graf J, Bals R, Vogelmeier CF, Jörres RA.

Respir Res. 2019 Mar 27;20(1):61. doi: 10.1186/s12931-019-1025-y.

19.

[Orphan drugs].

Schäfer JR, Vogelmeier CF.

Internist (Berl). 2019 Apr;60(4):396-398. doi: 10.1007/s00108-019-0582-y. German. No abstract available.

PMID:
30859277
20.

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019.

Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Criner GJ, Frith P, Halpin DMG, Han M, López Varela MV, Martinez F, Montes de Oca M, Papi A, Pavord ID, Roche N, Sin DD, Stockley R, Vestbo J, Wedzicha JA, Vogelmeier C.

Eur Respir J. 2019 May 18;53(5). pii: 1900164. doi: 10.1183/13993003.00164-2019. Print 2019 May. Review.

PMID:
30846476
21.

Treatment response in COPD: does FEV1 say it all? A post hoc analysis of the CRYSTAL study.

Kostikas K, Greulich T, Mackay AJ, Lossi NS, Aalamian-Mattheis M, Nunez X, Pagano VA, Patalano F, Clemens A, Vogelmeier CF.

ERJ Open Res. 2019 Feb 25;5(1). pii: 00243-2018. doi: 10.1183/23120541.00243-2018. eCollection 2019 Feb.

22.

Artificial intelligence outperforms pulmonologists in the interpretation of pulmonary function tests.

Topalovic M, Das N, Burgel PR, Daenen M, Derom E, Haenebalcke C, Janssen R, Kerstjens HAM, Liistro G, Louis R, Ninane V, Pison C, Schlesser M, Vercauter P, Vogelmeier CF, Wouters E, Wynants J, Janssens W; Pulmonary Function Study Investigators; Pulmonary Function Study Investigators:.

Eur Respir J. 2019 Apr 11;53(4). pii: 1801660. doi: 10.1183/13993003.01660-2018. Print 2019 Apr.

PMID:
30765505
23.

Effect of COPD severity and comorbidities on the result of the PHQ-9 tool for the diagnosis of depression: results from the COSYCONET cohort study.

von Siemens SM, Jörres RA, Behr J, Alter P, Lutter J, Lucke T, Söhler S, Welte T, Watz H, Vogelmeier CF, Trudzinski F, Rief W, Herbig B, Kahnert K; COSYCONET study group.

Respir Res. 2019 Feb 11;20(1):30. doi: 10.1186/s12931-019-0997-y.

24.

[Perspectives 2025 - Positions of the German Society of Internal Medicine].

Vogelmeier C, Floege J, Gamstätter T.

Dtsch Med Wochenschr. 2019 Feb;144(3):207-212. doi: 10.1055/a-0799-5146. Epub 2019 Jan 31. German.

PMID:
30703843
25.

Spirometric changes during exacerbations of COPD: a post hoc analysis of the WISDOM trial.

Watz H, Tetzlaff K, Magnussen H, Mueller A, Rodriguez-Roisin R, Wouters EFM, Vogelmeier C, Calverley PMA.

Respir Res. 2018 Dec 13;19(1):251. doi: 10.1186/s12931-018-0944-3.

26.

Current Controversies in Chronic Obstructive Pulmonary Disease. A Report from the Global Initiative for Chronic Obstructive Lung Disease Scientific Committee.

Criner GJ, Martinez FJ, Aaron S, Agusti A, Anzueto A, Bafadhel M, Barnes PJ, Bourbeau J, Chen R, Ewig J, Fabbri LM, Frith P, Halpin DMG, Han M, Montes de Oca M, Nishimura M, O'Donnell D, Papi A, Pavord I, Roche N, Rodriguez-Roisin R, Salvi S, Singh D, Sin DD, Stockley R, López Varela MV, Vestbo J, Vogelmeier CF, Washko G, Wedzicha JA, Celli BR.

Ann Am Thorac Soc. 2019 Jan;16(1):29-39. doi: 10.1513/AnnalsATS.201808-557PS. No abstract available.

PMID:
30427736
27.

[Guideline for the Diagnosis and Treatment of Asthma - Guideline of the German Respiratory Society and the German Atemwegsliga in Cooperation with the Paediatric Respiratory Society and the Austrian Society of Pneumology].

Buhl R, Bals R, Baur X, Berdel D, Criée CP, Gappa M, Gillissen A, Greulich T, Haidl P, Hamelmann E, Kardos P, Kenn K, Klimek L, Korn S, Lommatzsch M, Magnussen H, Nicolai T, Nowak D, Pfaar O, Rabe KF, Riedler J, Ritz T, Schultz K, Schuster A, Spindler T, Taube C, Taube K, Vogelmeier C, von Leupoldt A, Wantke F, Weise S, Wildhaber J, Worth H, Zacharasiewicz A.

Pneumologie. 2017 Dec;71(12):e3. doi: 10.1055/a-0790-0021. Epub 2018 Nov 7. German. No abstract available.

PMID:
30406626
28.

The LEAD (Lung, Heart, Social, Body) Study: Objectives, Methodology, and External Validity of the Population-Based Cohort Study.

Breyer-Kohansal R, Hartl S, Burghuber OC, Urban M, Schrott A, Agusti A, Sigsgaard T, Vogelmeier C, Wouters E, Studnicka M, Breyer MK.

J Epidemiol. 2019 Aug 5;29(8):315-324. doi: 10.2188/jea.JE20180039. Epub 2018 Oct 20.

29.

Longitudinal stability of blood eosinophil count strata in the COPD COSYCONET cohort.

Greulich T, Mager S, Lucke T, Koczulla AR, Bals R, Fähndrich S, Jörres RA, Alter P, Kirsten A, Vogelmeier CF, Watz H.

Int J Chron Obstruct Pulmon Dis. 2018 Sep 28;13:2999-3002. doi: 10.2147/COPD.S165909. eCollection 2018. No abstract available.

30.

Medical Treatment of COPD.

Graf J, Jörres RA, Lucke T, Nowak D, Vogelmeier CF, Ficker JH.

Dtsch Arztebl Int. 2018 Sep 14;155(37):599-605. doi: 10.3238/arztebl.2018.0599.

31.

Proviral MicroRNAs Detected in Extracellular Vesicles From Bronchoalveolar Lavage Fluid of Patients With Influenza Virus-Induced Acute Respiratory Distress Syndrome.

Scheller N, Herold S, Kellner R, Bertrams W, Jung AL, Janga H, Greulich T, Schulte LN, Vogelmeier CF, Lohmeyer J, Schmeck B.

J Infect Dis. 2019 Jan 29;219(4):540-543. doi: 10.1093/infdis/jiy554.

PMID:
30239899
32.

Safety of biweekly α1-antitrypsin treatment in the RAPID programme.

Greulich T, Chlumsky J, Wencker M, Vit O, Fries M, Chung T, Shebl A, Vogelmeier C, Chapman KR, McElvaney NG; RAPID Trial Group.

Eur Respir J. 2018 Nov 29;52(5). pii: 1800897. doi: 10.1183/13993003.00897-2018. Print 2018 Nov. No abstract available.

33.

[Control of Respiratory Symptoms During Sleep in Patients with Stable Bronchial Asthma].

Guenter K, Cassel W, Hildebrandt O, Kroenig J, Fischer P, Weissflog A, Vogelmeier C, Koehler U.

Dtsch Med Wochenschr. 2018 Sep;143(18):e159-e164. doi: 10.1055/a-0623-8651. Epub 2018 Sep 10. German.

PMID:
30199906
34.

Dual bronchodilation vs triple therapy in the "real-life" COPD DACCORD study.

Buhl R, Criée CP, Kardos P, Vogelmeier CF, Kostikas K, Lossi NS, Worth H.

Int J Chron Obstruct Pulmon Dis. 2018 Aug 24;13:2557-2568. doi: 10.2147/COPD.S169958. eCollection 2018.

35.

Influence of body mass on predicted values of static hyperinflation in COPD.

Alter P, Rabe KF, Schulz H, Vogelmeier CF, Jörres RA.

Int J Chron Obstruct Pulmon Dis. 2018 Aug 23;13:2551-2555. doi: 10.2147/COPD.S164096. eCollection 2018.

36.

COPD as a risk factor of the complications in lower limb arthroplasty: a patient-matched study.

Klasan A, Dworschak P, Heyse TJ, Ruchholtz S, Alter P, Vogelmeier CF, Schwarz P.

Int J Chron Obstruct Pulmon Dis. 2018 Aug 21;13:2495-2499. doi: 10.2147/COPD.S161577. eCollection 2018.

37.

[The lung in systemic diseases : Between holistic and individualized medicine-a challenge for internal medicine].

Welte T, Vogelmeier C, Hiddemann W, Märker-Hermann E.

Internist (Berl). 2018 Sep;59(9):873-875. doi: 10.1007/s00108-018-0481-7. German. No abstract available.

PMID:
30143815
38.

Real world evaluation of a novel lateral flow assay (AlphaKit® QuickScreen) for the detection of alpha-1-antitrypsin deficiency.

Greulich T, Rodríguez-Frias F, Belmonte I, Klemmer A, Vogelmeier CF, Miravitlles M.

Respir Res. 2018 Aug 13;19(1):151. doi: 10.1186/s12931-018-0826-8.

39.

[Antibiotics: The Most Important Discovery in Medicine of the 20th Century].

Vogelmeier CF.

Dtsch Med Wochenschr. 2018 Aug;143(15):1057. doi: 10.1055/a-0606-1729. Epub 2018 Jul 30. German. No abstract available.

PMID:
30060272
40.

Genome-wide MicroRNA Expression Profiles in COPD: Early Predictors for Cancer Development.

Keller A, Fehlmann T, Ludwig N, Kahraman M, Laufer T, Backes C, Vogelmeier C, Diener C, Biertz F, Herr C, Jörres RA, Lenhof HP, Meese E, Bals R; COSYCONET Study Group.

Genomics Proteomics Bioinformatics. 2018 Jun;16(3):162-171. doi: 10.1016/j.gpb.2018.06.001. Epub 2018 Jul 5.

41.

Design and application of an MR reference phantom for multicentre lung imaging trials.

Triphan SMF, Biederer J, Burmester K, Fellhauer I, Vogelmeier CF, Jörres RA, Kauczor HU, Heußel CP, Wielpütz MO, Jobst BJ.

PLoS One. 2018 Jul 5;13(7):e0199148. doi: 10.1371/journal.pone.0199148. eCollection 2018.

42.

Uric acid, lung function, physical capacity and exacerbation frequency in patients with COPD: a multi-dimensional approach.

Kahnert K, Alter P, Welte T, Huber RM, Behr J, Biertz F, Watz H, Bals R, Vogelmeier CF, Jörres RA.

Respir Res. 2018 Jun 4;19(1):110. doi: 10.1186/s12931-018-0815-y.

43.

Health status in patients with COPD treated with roflumilast: two large noninterventional real-life studies: DINO and DACOTA.

Kardos P, Mokros I, Sauer R, Vogelmeier CF.

Int J Chron Obstruct Pulmon Dis. 2018 May 3;13:1455-1468. doi: 10.2147/COPD.S159827. eCollection 2018.

44.

Relationship of spirometric, body plethysmographic, and diffusing capacity parameters to emphysema scores derived from CT scans.

Kahnert K, Jobst B, Biertz F, Biederer J, Watz H, Huber RM, Behr J, Grenier PA, Alter P, Vogelmeier CF, Kauczor HU, Jörres RA.

Chron Respir Dis. 2019 Jan-Dec;16:1479972318775423. doi: 10.1177/1479972318775423. Epub 2018 May 9.

45.

Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study.

Greulich T, Kostikas K, Gaga M, Aalamian-Mattheis M, Lossi NS, Patalano F, Nunez X, Pagano VA, Fogel R, Vogelmeier CF, Clemens A.

Int J Chron Obstruct Pulmon Dis. 2018 Apr 16;13:1229-1237. doi: 10.2147/COPD.S159732. eCollection 2018.

46.

Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study.

Vogelmeier CF, Chapman KR, Miravitlles M, Roche N, Vestbo J, Thach C, Banerji D, Fogel R, Patalano F, Olsson P, Kostikas K, Wedzicha JA.

Int J Chron Obstruct Pulmon Dis. 2018 Apr 10;13:1125-1134. doi: 10.2147/COPD.S160011. eCollection 2018.

47.

Pharmacological treatment of COPD: the devil is always in the detail.

Singh D, Barnes PJ, Stockley R, Lopez Valera MV, Vogelmeier C, Agusti A.

Eur Respir J. 2018 Apr 19;51(4). pii: 1800263. doi: 10.1183/13993003.00263-2018. Print 2018 Apr. No abstract available.

48.

Left ventricular volume and wall stress are linked to lung function impairment in COPD.

Alter P, Jörres RA, Watz H, Welte T, Gläser S, Schulz H, Bals R, Karch A, Wouters EFM, Vestbo J, Young D, Vogelmeier CF.

Int J Cardiol. 2018 Jun 15;261:172-178. doi: 10.1016/j.ijcard.2018.02.074.

PMID:
29657040
49.

Blood eosinophils as a marker of eosinophilic exacerbations in COPD.

Greulich T, Vogelmeier CF.

Lancet Respir Med. 2018 May;6(5):e17. doi: 10.1016/S2213-2600(18)30095-X. Epub 2018 Apr 5. No abstract available.

PMID:
29627195
50.

A GATA3-specific DNAzyme attenuates sputum eosinophilia in eosinophilic COPD patients: a feasibility randomized clinical trial.

Greulich T, Hohlfeld JM, Neuser P, Lueer K, Klemmer A, Schade-Brittinger C, Harnisch S, Garn H, Renz H, Homburg U, Renz J, Kirsten A, Pedersen F, Müller M, Vogelmeier CF, Watz H.

Respir Res. 2018 Apr 4;19(1):55. doi: 10.1186/s12931-018-0751-x.

Supplemental Content

Loading ...
Support Center